Families Sue Administration Over Medicaid Funding Rule
Four New Hampshire families are challenging a federal restriction on Medicaid funding for gender-affirming care.
Updated on Oct. 30, 2026 in Allergies
Four New Hampshire families filed a lawsuit against the Trump administration following a federal rule that took effect on October 13, 2026, prohibiting Medicaid and CHIP coverage for gender-affirming care. The plaintiffs argue the policy causes irreparable harm to youth who are now unable to access necessary medical treatments.
Why it matters
The lawsuit challenges whether the Centers for Medicare & Medicaid Services has the authority to implement these coverage exclusions. Federal officials maintain that these procedures have irreversible consequences and are not beneficial for young people.
A federal rule took effect on October 13, 2026, barring Medicaid and CHIP benefits for gender dysphoria medication. The litigation involves four New Hampshire families, including a Hillsborough County teenager denied puberty blockers.
The players
Trump administration
The current executive branch of the United States government responsible for implementing federal agency policies.
Centers for Medicare & Medicaid Services
The federal agency within the Department of Health and Human Services that administers the nation's Medicaid and CHIP programs.
The details
The plaintiffs are seeking a preliminary injunction to maintain access to medical care while the case proceeds through federal court. This legal action follows a 2025 state-level ban in New Hampshire that already restricted gender-affirming care for new patients under the age of 18.
Timeline
New Hampshire banned gender-affirming care for new patients under 18 in 2025.
A federal rule restricting Medicaid coverage for these services took effect on October 13, 2026.
A decision on the requested preliminary injunction is expected within several weeks.
The lawsuit is expected to take years to reach a final resolution.
Health Landscape
This lawsuit marks a major legal challenge to the Medicaid and CHIP funding rules for gender-affirming care. It highlights a widening divide between federal regulatory policy and families seeking access to specialized pediatric treatments.
Families relying on Medicaid or CHIP for gender dysphoria treatments face immediate barriers to care following the recent rule change. This legal battle will determine whether these individuals can continue to access specific medications and services during ongoing litigation.
The takeaway
The court's decision on the preliminary injunction will serve as a critical indicator for how federal coverage restrictions will be handled in the near term. Affected families must monitor their state's Medicaid guidelines as the legal process unfolds at the federal level.
What happens next
A decision on the preliminary injunction is expected in the coming weeks, while the lawsuit itself is expected to take years to reach a final resolution.
Further reading
Learn more about federal health policy coverage in the Allergies section.
Source note: This article includes information reported by Concord Monitor.
